New antibody drug targets Hard-to-Treat cancers in early trial
NCT ID NCT06547840
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing an experimental drug called MOv18 IgE in people with advanced ovarian, endometrial, or triple-negative breast cancers that have a specific protein (folate receptor alpha) on their cells. The study has two parts: first, finding the safest dose, and then checking if the drug can shrink tumors. About 45 participants will be enrolled to see if the drug is safe and shows promise.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MOv18 IgE (an experimental antibody designed to target cancer cells)
- What this could lead to
- If it works, this could lead to a new treatment option for certain hard-to-treat cancers like platinum-resistant ovarian cancer.
- What could go wrong
- This is an early Phase 1 trial with only 45 participants, so it is primarily testing safety and dosing. The drug may not show enough anti-tumor activity or could cause unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED ENDOMETRIAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Bristol Haematology and Oncology Centre
RECRUITINGBristol, BS2 8ED, United Kingdom
-
Cambridge University - Addenbrooke's Hospital
RECRUITINGLondon, CB2 0QQ, United Kingdom
-
Edinburgh Cancer Research Centre
RECRUITINGEdinburgh, EH4 2XR, United Kingdom
-
Guy's Hospital
RECRUITINGLondon, SE1 3SS, United Kingdom
-
Leeds Teaching Hospitals NHS Trust
RECRUITINGLeeds, LS9 7LP, United Kingdom
-
University College London Hospital
RECRUITINGLondon, NW1 2BU, United Kingdom
-
University Hospital Southampton NHS Foundation Trust
RECRUITINGSouthampton, SO16 6HU, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a Four-Drug combo erase Triple-Negative breast cancer before surgery?
- What raises endometrial cancer risk in black women? a study digs in
- Can a Custom-Made vaccine outsmart Triple-Negative breast cancer?
- Can a High-Fiber diet shield the gut during breast cancer therapy?
- Can a drug combo outsmart a tough breast cancer subtype?